BioRegenx Inc (OTC: BRGX) is a health and wellness company that markets microvascular health diagnostic devices, dietary supplements, and telehealth-adjacent technology products through its subsidiaries. Revenue is generated through product sales of the MyBodyRx branded supplement line (including the patented Endocalyx Pro), GlycoCheck microvascular diagnostic devices, and health and wellness hardware such as Pulsed Electro-Magnetic Field devices and class II Electronic Muscle Stimulation therapy devices, distributed via affiliates, practitioners, and direct-to-consumer channels. The company also operates Findit AI Connect, a digital marketing and content platform intended for white-label licensing and affiliate monetization. BioRegenx operates through subsidiary NuLife Sciences, Inc. and MicroVascular Health Solutions, LLC, and is developing subscription-based software services and AI-driven health scanning apps including TruScan.AI. The company was originally incorporated in Nevada on December 23, 1998 as Findit, Inc., and changed its name to BioRegenx Inc. following a merger effective March 8, 2024.

Revenue model

Product sales of supplements and health devices through affiliate networks, practitioners, and direct-to-consumer channels; royalty agreements related to GlycoCheck technology; planned subscription-based software licensing for GlycoCheck and AI-driven health apps; white-label licensing of Findit AI Connect tools to affiliate partners.

Products and services

MyBodyRx branded supplement line including patented Endocalyx Pro; GlycoCheck microvascular diagnostic device; hydrogen water products; Pulsed Electro-Magnetic Field devices; StimaWELL and ReLounge class II Electronic Muscle Stimulation therapy devices; Findit AI Connect digital marketing and automation platform; TruScan.AI mobile app (in development as of the 10-K filed 2026-04-15) covering vitals, nutrients, wellness, and skin health metrics; VitalWellness app; DNA and epigenetics testing products and services (in development).

Customers and end markets

Academic research institutions validating scientific methodologies; healthcare facilities including diagnostic laboratories and emergency care units; direct-to-consumer wellness buyers; supplement wholesalers; practitioner clinics; wellness centers; B2B healthcare institutions targeted for the DOCSUN AI Engine.

Value-chain role

Downstream marketer and distributor of health and wellness devices and supplements; technology developer of AI-driven health scanning apps in collaboration with third-party AI engine providers (DocSun); operator of a digital content and affiliate marketing platform.

Geographic exposure

The company describes itself as global and operates remotely; no specific country or regional revenue breakdown is disclosed in the filing excerpts.

Competitors

Teladoc Health, Amwell, MDLIVE, Google, Bing, Yahoo

Source: SEC 10-K, filed 2026-04-15

Industry: Services-Computer Programming, Data Processing, Etc. Peers: FOMO WORLDWIDE, INC. Alphabet Inc /entities/lbuy AutoWeb, Inc. Beyond Commerce Inc Creatd Inc Good Gaming Inc Onfolio Holdings Inc